Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Aiqin Zhike Granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Aiqin Zhike Granules: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
VSF-173 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
VSF-173: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Olamkicept Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Olamkicept: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Perillyl alcohol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Perillyl alcohol: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
LT-002 (LeadingTac) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
LT-002 (LeadingTac): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ASP-7035 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
ASP-7035: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
BBD-1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
BBD-1: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Fully Human Anti-tetanus Toxin Monoclonal Antibody A82/B86(Changchun BCHT Biotechnology Co.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Fully Human Anti-tetanus Toxin Monoclonal Antibody A82/B86(Changchun BCHT Biotechnology Co.): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clini
9 min read
ND-003 (NewDEL Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
ND-003 (NewDEL Biotech): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
RX-0201 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
RX-0201: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ATX-304 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
ATX-304: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
CAStem Cell (Beijing Zehui Chenxing) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
CAStem Cell (Beijing Zehui Chenxing): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, a